NASDAQ:YI 111 (YI) Stock Price, News & Analysis $8.08 -0.10 (-1.22%) Closing price 03:59 PM EasternExtended Trading$8.24 +0.16 (+1.98%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About 111 Stock (NASDAQ:YI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 111 alerts:Sign Up Key Stats Today's Range$8.00▼$8.1550-Day Range$6.15▼$8.5352-Week Range$4.15▼$12.90Volume8,687 shsAverage Volume24,424 shsMarket Capitalization$69.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.Read More… 111 Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreYI MarketRank™: 111 scored higher than 18% of companies evaluated by MarketBeat, and ranked 875th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for 111. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of 111 is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 111 is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about 111's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of 111 has been sold short.Short Interest Ratio / Days to Cover111 has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 111 has recently decreased by 32.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield111 does not currently pay a dividend.Dividend Growth111 does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the float of 111 has been sold short.Short Interest Ratio / Days to Cover111 has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 111 has recently decreased by 32.73%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.09 News Sentiment111 has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for 111 this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 111 insiders have not sold or bought any company stock.Percentage Held by Insiders43.90% of the stock of 111 is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.32% of the stock of 111 is held by institutions.Read more about 111's insider trading history. Receive YI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 111 and its competitors with MarketBeat's FREE daily newsletter. Email Address YI Stock News HeadlinesCollision in Duplin County claims two lives, leaves two injured on Highway 111June 12 at 11:54 AM | msn.com111 (NASDAQ:YI) investors are sitting on a loss of 87% if they invested five years agoJune 10 at 4:40 PM | uk.finance.yahoo.comGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powerful is happening behind the scenes… Some investors are using a little-known ETF to collect up to $1,152/month from gold's surge. No trading gold futures. No mining stocks. No vaults. Just a simple fund delivering monthly payouts — like clockwork.June 13, 2025 | Investors Alley (Ad)Immersive Domes, Checkered-Eared Rabbits and a New Streaming Platform: Hungary to Showcase 111 Years of Animation as Annecy Country of HonorJune 9, 2025 | msn.comPhotos: Best images from Thunder's 111-110 Game 1 loss to PacersJune 7, 2025 | msn.comAlert: The Indiana Pacers beat the Oklahoma City Thunder 111-110 in Game 1 of the NBA FinalsJune 6, 2025 | chron.comPacers stun Thunder, 111-110, in Game 1 of NBA Finals behind huge rallyJune 6, 2025 | msn.comGood news and bad news from dominant 111-94 Game 5 win over PacersMay 30, 2025 | msn.comSee More Headlines YI Stock Analysis - Frequently Asked Questions How have YI shares performed this year? 111's stock was trading at $6.23 at the beginning of 2025. Since then, YI shares have increased by 29.7% and is now trading at $8.08. View the best growth stocks for 2025 here. How were 111's earnings last quarter? 111, Inc. (NASDAQ:YI) announced its earnings results on Thursday, March, 20th. The company reported ($0.04) EPS for the quarter. The firm earned $527.14 million during the quarter. Read the conference call transcript. When did 111's stock split? 111 shares reverse split on the morning of Friday, January 24th 2025. The 1-10 reverse split was announced on Wednesday, January 8th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 23rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did 111 IPO? 111 (YI) raised $140 million in an initial public offering (IPO) on Wednesday, September 12th 2018. The company issued 9,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup and CICC acted as the underwriters for the IPO. Who are 111's major shareholders? 111's top institutional shareholders include Connor Clark & Lunn Investment Management Ltd. (0.13%) and Deuterium Capital Management LLC (0.12%). How do I buy shares of 111? Shares of YI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 111 own? Based on aggregate information from My MarketBeat watchlists, some other companies that 111 investors own include NVIDIA (NVDA), Teladoc Health (TDOC), Innovative Industrial Properties (IIPR), Magnite (MGNI), Roku (ROKU), Twilio (TWLO). Company Calendar Last Earnings3/20/2025Today6/13/2025Next Earnings (Estimated)6/19/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug stores & proprietary stores Sub-IndustryRetail Current SymbolNASDAQ:YI CIK1738906 Webwww.111.com.cn Phone862120536666FaxN/AEmployees2,110Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.07 million Net Margins-1.75% Pretax Margin-1.48% Return on EquityN/A Return on Assets-8.67% Debt Debt-to-Equity RatioN/A Current Ratio1.09 Quick Ratio0.51 Sales & Book Value Annual Sales$14.40 billion Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($9.79) per share Price / Book-0.82Miscellaneous Outstanding Shares8,644,000Free Float4,798,000Market Cap$69.20 million OptionableOptionable Beta0.47 20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free Report This page (NASDAQ:YI) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 111, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 111 With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.